Cost is the reason most people start thinking about switching from Zepbound to Foundayo in the first place. Both medications come from Eli Lilly, both target weight management, and both work through GLP-1 receptor activation. But their price tags are not remotely similar. Understanding exactly how much you will save — and under which circumstances — requires looking beyond the list price.
This guide breaks down the real-world cost of Zepbound versus Foundayo across every common payment scenario: commercial insurance with copays, savings card pricing, LillyDirect self-pay, Medicare Part D, and full cash pay. We include dose-level specifics because your actual cost depends heavily on where you are in your titration.
Quick Answer
For most patients, switching from Zepbound to Foundayo saves between $3,000 and $10,000 per year depending on your insurance situation. With Lilly's $25/month savings card, eligible commercially insured patients can get Foundayo for $25/month compared to Zepbound's typical copay of $25–$150/month (when covered) or $1,000+/month at list price. The biggest savings accrue to self-pay patients using LillyDirect, where Foundayo is dramatically cheaper than Zepbound at every dose level.
Zepbound Pricing Breakdown
Zepbound (tirzepatide) is available in five dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, and 15 mg. It is administered as a weekly subcutaneous injection.
List Price
Zepbound's wholesale acquisition cost (WAC) is approximately $1,059.87 per month (4-week supply) across all dose strengths. This is the price before any discounts, rebates, or insurance negotiation.
LillyDirect Self-Pay Pricing
Eli Lilly offers Zepbound through LillyDirect for patients paying out of pocket. As of April 2026, LillyDirect pricing for Zepbound single-dose vials is:
- 2.5 mg: ~$399/month
- 5 mg: ~$549/month
- 7.5 mg: ~$549/month
- 10 mg: ~$549/month
- 15 mg: ~$549/month
These prices apply to the single-dose vial program. The standard auto-injector pen at pharmacies costs significantly more without insurance.
Zepbound Savings Card
Lilly offers a savings card for commercially insured patients that can reduce copays to as low as $25/month. Eligibility requires commercial insurance that covers Zepbound. Patients on Medicare, Medicaid, or other government programs are not eligible for the commercial savings card.
Foundayo Pricing Breakdown
Foundayo (orforglipron) is an oral daily tablet. It launched with aggressive pricing designed to undercut the injectable GLP-1 market. For complete pricing details, see our Foundayo pricing guide.
List Price
Foundayo's list price is approximately $449/month — less than half of Zepbound's list price. This pricing signals Lilly's intent to make Foundayo accessible as a high-volume, lower-margin product.
LillyDirect Self-Pay Pricing
Through LillyDirect, Foundayo is available at even lower self-pay pricing:
- Starting doses (titration): ~$149/month
- Maintenance doses: ~$199–$299/month
Foundayo Savings Card ($25/month)
The headline number: eligible commercially insured patients can get Foundayo for $25/month using Lilly's savings card program. This is the same structure as the Zepbound savings card but applies to a medication with a lower list price, which means more plans are likely to cover it and the savings card covers a smaller gap.
Head-to-Head Cost Comparison
| Scenario | Zepbound (monthly) | Foundayo (monthly) | Monthly Savings | Annual Savings |
|---|---|---|---|---|
| List price (no insurance) | $1,059 | $449 | $610 | $7,320 |
| LillyDirect self-pay (maintenance dose) | $549 | $199–$299 | $250–$350 | $3,000–$4,200 |
| Commercial insurance + savings card | $25 | $25 | $0 | $0 |
| Commercial insurance, no savings card | $50–$150 copay | $30–$75 copay | $20–$75 | $240–$900 |
| Insurance denies coverage | $1,059 (or LillyDirect) | $449 (or LillyDirect) | $610+ | $7,320+ |
| Medicare Part D (2026 Bridge) | $50/month (if eligible) | $50/month (Lilly program) | $0 | $0 |
Key takeaway: The savings are largest for self-pay and uninsured patients. If you have good commercial insurance with a savings card for both medications, the out-of-pocket cost may be identical at $25/month. The real cost advantage of Foundayo shows up when insurance is problematic.
Annual Savings Calculation
Let us walk through three realistic scenarios to show what the switch means in actual dollars over a year.
Scenario 1: Self-Pay Patient Using LillyDirect
- Zepbound at 10 mg via LillyDirect: $549/month × 12 = $6,588/year
- Foundayo at maintenance dose via LillyDirect: $249/month × 12 = $2,988/year
- Annual savings: $3,600
Scenario 2: Commercially Insured, Zepbound Requires Prior Auth
- Zepbound denied, paying list: $1,059/month × 12 = $12,708/year
- Foundayo covered with $50 copay: $50/month × 12 = $600/year
- Annual savings: $12,108
Scenario 3: Both Covered with Savings Cards
- Zepbound with savings card: $25/month × 12 = $300/year
- Foundayo with savings card: $25/month × 12 = $300/year
- Annual savings: $0 (no cost advantage to switching)
The pattern is clear: the worse your Zepbound coverage, the more you save by switching to Foundayo.
Insurance Coverage Scenarios
Commercial Insurance
Foundayo has an advantage in formulary placement. Because it is oral (lower distribution cost), newer (Lilly is actively negotiating placement), and lower-priced (smaller rebate gap for PBMs), it tends to land on more formularies with lower tier placement than Zepbound. If your Zepbound coverage has been inconsistent — prior authorizations, step therapy requirements, or tier changes — Foundayo may offer a smoother coverage path.
Medicare Part D
As of 2026, both Zepbound and Foundayo are available to Medicare beneficiaries through specific programs. The CMS Bridge Program (July–December 2026) covers Zepbound and Wegovy at $50/month for eligible Part D enrollees. Separately, Lilly has committed to making Foundayo available at $50/month for Medicare patients starting July 2026. In this scenario, the cost is identical.
No Insurance / Self-Pay
This is where Foundayo wins decisively. At every price point — list, LillyDirect, or discount pharmacy — Foundayo costs substantially less than Zepbound. If you are paying entirely out of pocket, the switch can save you $250–$600+ per month.
The LillyDirect Factor
LillyDirect deserves its own discussion because it fundamentally changes the cost equation for both medications. By selling directly to patients through its own pharmacy fulfillment, Lilly bypasses PBM markups and pharmacy margins.
For Zepbound, LillyDirect introduced single-dose vials at lower prices than the auto-injector pens available at retail pharmacies. For Foundayo, LillyDirect offers the lowest available self-pay pricing from day one.
If you are considering the switch primarily for cost reasons and you do not have insurance coverage for either medication, LillyDirect pricing for Foundayo is likely your best option. The combination of a lower list price, direct-to-consumer distribution, and savings card eligibility creates the most favorable cost structure in the current GLP-1 market.
When Cost Should (and Shouldn't) Drive the Decision
Cost is a legitimate reason to switch medications. Nobody should go bankrupt for appetite suppression. But cost should be weighed against clinical factors:
Cost should drive the switch when:
- You are at or near your goal weight and maintaining
- Your Zepbound coverage has been denied or is unreliable
- You are paying more than $300/month out of pocket for Zepbound
- You would otherwise stop GLP-1 therapy entirely due to affordability
- Foundayo's efficacy is sufficient for your current needs
Cost alone should not drive the switch when:
- You are mid-loss with significant weight still to lose and responding well to Zepbound
- You have type 2 diabetes that benefits from the dual GIP/GLP-1 mechanism
- Your Zepbound is covered at $25/month with a savings card (no cost difference)
- You have tried other GLP-1 agonists and only responded well to tirzepatide's dual mechanism
Bottom Line
Foundayo is meaningfully cheaper than Zepbound in almost every payment scenario except when both are fully covered by insurance with savings cards. Self-pay patients save the most — potentially $3,600 to $12,000+ per year. The cost advantage is real, substantial, and one of the strongest reasons to consider the switch for patients who are clinically appropriate candidates.
Before making a purely financial decision, review the clinical considerations in our complete Zepbound to Foundayo switching guide and discuss the trade-offs with your healthcare provider. The cheapest medication is not always the right medication — but when efficacy is comparable and you are paying thousands less, the math speaks for itself.
Sources
- Eli Lilly and Company. Foundayo (orforglipron) Pricing and Access Information. LillyDirect.com. 2026.
- Eli Lilly and Company. Zepbound (tirzepatide) Pricing, Savings Card, and LillyDirect Programs. Zepbound.lilly.com. 2026.
- Centers for Medicare & Medicaid Services. 2026 Medicare Part D Benefit Parameters and Bridge Program Details. CMS.gov.
- GoodRx. Zepbound and Foundayo Cash Price Comparisons. GoodRx.com. Accessed April 2026.
- Eli Lilly. "Commitment to Access: Foundayo Pricing Strategy." Investor Relations Materials. 2026.